Is Atera’s New Spatial Biology Platform Altering The Investment Case For 10x Genomics (TXG)?

Simply Wall St.04-22

10x Genomics has launched Atera, an in situ spatial biology platform offering whole-transcriptome, single-cell–sensitivity analysis at scale across fresh-frozen and FFPE tissues, with pre-orders open ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629052361?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-04-22 01:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629052361","market":"nz","top_or_hot":-1,"title":"Is Atera’s New Spatial Biology Platform Altering The Investment Case For 10x Genomics (TXG)?","media":"Simply Wall St.","content":"<div>\n<p>10x Genomics has launched Atera, an in situ spatial biology platform offering whole-transcriptome, single-cell–sensitivity analysis at scale across fresh-frozen and FFPE tissues, with pre-orders open ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-txg/10x-genomics/news/is-ateras-new-spatial-biology-platform-altering-the-investme\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Atera’s New Spatial Biology Platform Altering The Investment Case For 10x Genomics (TXG)?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Atera’s New Spatial Biology Platform Altering The Investment Case For 10x Genomics (TXG)?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-22 01:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-txg/10x-genomics/news/is-ateras-new-spatial-biology-platform-altering-the-investme><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>10x Genomics has launched Atera, an in situ spatial biology platform offering whole-transcriptome, single-cell–sensitivity analysis at scale across fresh-frozen and FFPE tissues, with pre-orders open ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-txg/10x-genomics/news/is-ateras-new-spatial-biology-platform-altering-the-investme\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4528","symbol_name":"SaaS概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-txg/10x-genomics/news/is-ateras-new-spatial-biology-platform-altering-the-investme","article_id":"2629052361","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-txg/10x-genomics/news/is-ateras-new-spatial-biology-platform-altering-the-investme","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2629052361","pubTimestamp":1776791081,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"10x Genomics has launched Atera, an in situ spatial biology platform offering whole-transcriptome, single-cell–sensitivity analysis at scale across fresh-frozen and FFPE tissues, with pre-orders open and shipments targeted for the second half of 2026.\nEarly Atera data from leading groups like the June Lab and the German Cancer Research Center suggest the platform can reveal previously hidden tumor–immune interactions that may reshape research and drug discovery approaches.\nWe’ll now examine...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4528":"SaaS概念","BK4588":"碎股","AGIX":"通用人工智能 ETF-AGIX","BK4585":"ETF&股票定投概念","BK4023":"应用软件","AIPO":"Defiance AI and Power Infrastructure ETF","TXG":"10x Genomics, Inc.","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","AIYY":"YIELDMAX AI OPTION INCOME STRATEGY ETF","ARTY":"ISHARES FUTURE AI & TECH ETF","BK4121":"生命科学工具和服务","BK4543":"AI","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","AI":"C3.ai, Inc.","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","BK4587":"ChatGPT概念"},"translate_title":"Atera的新空间生物学平台是否会改变10x Genomics(TXG)的投资案例？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIPO":0.62,"CHAT":0.62,"AIYY":0.6,"TXG":1.5,"AI":0.62,"ARTY":0.62,"AGIX":0.62},"content_text":"10x Genomics has launched Atera, an in situ spatial biology platform offering whole-transcriptome, single-cell–sensitivity analysis at scale across fresh-frozen and FFPE tissues, with pre-orders open and shipments targeted for the second half of 2026. Early Atera data from leading groups like the June Lab and the German Cancer Research Center suggest the platform can reveal previously hidden tumor–immune interactions that may reshape research and drug discovery approaches. We’ll now examine how Atera’s whole-transcriptome, single-cell spatial capabilities could influence 10x Genomics’ existing investment narrative and long-term growth drivers. The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.Advertisement10x Genomics Investment Narrative RecapTo own 10x Genomics today, you have to believe that single cell and spatial biology will keep deepening their role in research and translational programs, and that 10x can stay at the center of that ecosystem despite ongoing losses and pricing pressure. Atera looks like an extension of that thesis rather than a near term turning point, with its 2026 shipment timeline meaning the key short term catalyst remains execution on existing platforms and consumables while funding and margin pressure stay the biggest risks. Among recent developments, the company’s February 2026 revenue outlook of US$600 million to US$625 million frames how Atera fits into expectations. Management has already said the launch was contemplated in that guide, so investors may watch upcoming quarters less for immediate Atera upside and more for signs that existing products like Chromium Flex, Visium HD and Xenium, along with new alliances in oncology and AI, can support that revenue range without further eroding profitability. Yet even if Atera gains traction, investors should be aware that continued pricing pressure and funding headwinds could still... Read the full narrative on 10x Genomics (it's free!)10x Genomics’ narrative projects $709.8 million in revenue and $110.2 million in earnings by 2029.Uncover how 10x Genomics' forecasts yield a $20.14 fair value, a 18% downside to its current price.Exploring Other PerspectivesTXG 1-Year Stock Price Chart Some of the lowest ranked analysts came in far more cautious, assuming roughly flat revenue around US$641.4 million and ongoing losses, while also warning that rapid commoditization in single cell and spatial tools could pressure pricing far more than the consensus currently implies.Explore 4 other fair value estimates on 10x Genomics - why the stock might be worth 48% less than the current price!The Verdict Is YoursDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your 10x Genomics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.Our free 10x Genomics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate 10x Genomics' overall financial health at a glance.Contemplating Other Strategies?Our daily scans reveal stocks with breakout potential. Don't miss this chance:Outshine the giants: these 19 early-stage AI stocks could fund your retirement.AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.The latest GPUs need a type of rare earth metal called Dysprosium and there are only 31 companies in the world exploring or producing it. Find the list for free.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629052361","isCrawlerRequest":true}